Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study.
Fiche publication
Date publication
mars 2023
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Dr DROUILLARD Antoine
Tous les auteurs :
Bergen ES, Pilla L, Auclin E, Ilhan-Mutlu A, Prager GW, Pietrantonio F, Antista M, Ghelardi F, Basile D, Aprile G, Longarini R, Hautefeuille V, Tougeron D, Artru P, Mabro M, Drouillard A, Roth G, Ben Abdelghani M, Clement I, Toullec C, Mineur L, Guimbaud R, Taieb J, Zaanan A
Lien Pubmed
Résumé
The optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma (OGA) remains challenging.
Mots clés
HER2, Maintenance therapy, Oeso-gastric cancer, Reintroduction therapy, Trastuzumab
Référence
Gastric Cancer. 2023 03 7;: